Trials / Completed
CompletedNCT02569476
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | |
| DRUG | Obinutuzumab |
Timeline
- Start date
- 2016-01-13
- Primary completion
- 2020-09-02
- Completion
- 2020-09-02
- First posted
- 2015-10-06
- Last updated
- 2024-10-26
- Results posted
- 2021-11-03
Locations
14 sites across 3 countries: United States, Australia, South Korea
Source: ClinicalTrials.gov record NCT02569476. Inclusion in this directory is not an endorsement.